Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

N/A(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07492745Not ApplicableRecruiting

Effect of Using a Reminder to Encourage Patients to be Active During Their Hospital Stay.

Role: collaborator

NCT04859608Phase 3Completed

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)

Role: collaborator

NCT04607967Not ApplicableRecruiting

HFNO or Conventional Oxygen Therapy for Patients With Acute Hypoxemic Respiratory Distress

Role: collaborator

NCT05302115Unknown

S-ICD French Cohort Study (HONEST)

Role: collaborator

NCT03991611Not ApplicableUnknown

Reducing Post-traumatic Stress Disorder After ICU Discharge With the IPREA3 Program

Role: lead

NCT02762409Completed

Improve the Quality of Life After a Hospitalization in Critical Care

Role: lead

NCT01002482Phase 3Completed

Computerized Glucose Control in Critically Ill Patients

Role: lead

NCT00240682Phase 2Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

Role: lead

All 8 trials loaded